Participants may not have had a history of intra-abdominal abscess within the past  months
History of abdominal fistula, gastrointestinal perforation, peptic ulcer, or intra-abdominal abscess within  months
History of abdominal fistula, intra-abdominal abscess, or gastrointestinal perforation within the last  months
No gastrointestinal disorders associated with a high risk of perforation or fistula formation within  months prior to registration:\r\n* Abdominal fistula\r\n* Gastrointestinal perforation\r\n* Intra-abdominal abscess; Note: Complete resolution of an intra-abdominal abscess must be confirmed prior to initiating treatment with cabozantinib even if the abscess occurred more than  months prior to registration
Patients with a history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within  days prior to beginning study treatment are NOT eligible for participation
History of abdominal fistula, gastrointestinal perforation, pneumothorax, or intra-abdominal abscess within  days of study enrollment
History of abdominal fistula, gastrointestinal perforation, intra-abdominal abscess, clinical signs or symptoms of gastrointestinaI obstruction or other known clinically signification gastrointestinal disease.
No history of abdominal fistula, gastrointestinal (GI) perforation, intra abdominal abscess, uncontrolled GI bleeding, diverticulitis within  months of study entry
Patients with a history of abdominal or tracheal-esophageal fistula, or gastrointestinal perforation are not eligible; patients with a history of intra-abdominal abscess within  months of enrollment
Active inflammatory gastrointestinal disease, chronic diarrhea (unless related to underlying malignancy or prior related treatment) or history of abdominal fistula, gastrointestinal perforation, peptic ulcer disease, or intra-abdominal abscess within  months prior to study enrollment. Gastroesophageal reflux disease under treatment with proton pump inhibitors is allowed.
intra-abdominal abscess within last  months prior to the first dose of study drug
History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within  days of study enrollment.
Patients who have a history of fistula, gastrointestinal ulcer or perforation, or intra-abdominal abscess within  months of study enrollment are not eligible
History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within  months prior to randomization.
Active inflammatory gastrointestinal disease, chronic diarrhea (unless related to underlying malignancy or prior related treatment) or history of abdominal fistula, gastrointestinal perforation, peptic ulcer disease, or intra-abdominal abscess within  months prior to study enrollment. Gastroesophageal reflux disease under treatment with proton pump inhibitors is allowed.
History of abdominal fistula, gastrointestinal perforation, or intraabdominal abscess within  months prior to starting treatment
History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within  months prior to day 
Has a known history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within  months prior to planned start of study drug
Serious or non-healing wound, ulcer, or bone fracture or history of abdominal fistula, gastrointestinal perforation, intra-abdominal abscess major surgical procedure, open biopsy, or significant traumatic injury within  days prior to registration, with the exception of the craniotomy for tumor resection
Active inflammatory gastrointestinal disease, chronic diarrhea (unless related to underlying malignancy or prior related treatment) or history of abdominal fistula, gastrointestinal perforation, peptic ulcer disease, or intra-abdominal abscess within  months prior to study enrollment; gastroesophageal reflux disease under treatment with proton pump inhibitors is allowed
History of abdominal fistula, gastrointestinal perforation, or intra- abdominal abscess within  days prior to registration.
Any of the following within  months before the first dose of study treatment:\r\n* Abdominal fistula\r\n* Gastrointestinal perforation\r\n* Bowel obstruction or gastric outlet obstruction\r\n* Intra-abdominal abscess; Note: complete resolution of an intra-abdominal abscess must be confirmed prior to initiating treatment with cabozantinib even if the abscess occurred more than  months before the first dose of study treatment
History of abdominal fistula, intra-abdominal abscess, or gastrointestinal perforation within the  months prior to enrollment
History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess =<  months prior to registration
Active inflammatory gastrointestinal disease such as chronic diarrhea (unless related to underlying malignancy or prior related treatment) or history of abdominal fistula, gastrointestinal perforation, peptic ulcer disease, or intra-abdominal abscess within  months prior to study enrollment; gastroesophageal reflux disease under treatment with proton pump inhibitors is allowed
Any of the following within  days of first date of study treatment: \r\n* Serious uncontrolled medical illness or disorder that in the opinion of the treating physician would make the patient ineligible for the study\r\n* Active uncontrolled infection (with the exception of uncomplicated urinary tract infection) \r\n* Abdominal fistula, gastrointestinal perforation or intra-abdominal abscess\r\n* Abdominal surgery (for reasons other than IP port placement)
PHASE I STUDY ELIGIBILITY CRITERIA:\r\nHistory of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within  months prior to study enrollment
PHASE II COLORECTAL CANCER COHORT  (MEDI+C ONLY):\r\nHistory of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within  months prior to study enrollment
History of intra-abdominal abscess within the past  months
History of abdominal fistula, gastrointestinal perforation, intra-abdominal abscess within six months prior to treatment start
History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within  days or manifestations of malabsorption due to prior gastrointestinal (GI) surgery or GI disease that may alter the absorption of MLN (TAK-)
Gastrointestinal perforation or intra-abdominal abscess (<  months); recent (<  months) gastrointestinal (GI) bleeding from gastric or duodenal ulcer
Patients with peptic ulcer, abdominal fistula, gastrointestinal perforation, intra-abdominal abscess within  months of registration
History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within  months prior to day 
History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within  months prior to day 
History of abdominal fistula, gastrointestinal (GI) perforation, or intra-abdominal abscess within  months of randomization
History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within  months prior to day 
History of an abdominal fistula, gastrointestinal (GI) perforation, or intra-abdominal abscess within previous  months
History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within  months prior to day  of study drug
History of abdominal fistula formation, gastrointestinal perforation, or abdominal abscess within six months
History of intra-abdominal abscess within the past  months
No evidence of a bowel obstruction, abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within  months of study entry
History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess in previous  months
Patients who have a history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within  days of study enrollment are not eligible
History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within  months prior to day 
History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within  months prior to day  of treatment
Patients must not have a history of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within  months prior to study entry
History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within  months prior to study enrollment
Patients with serious non-healing wound, ulcer, or bone fracture; this includes history of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within  days prior to the first date of study treatment; Note: Deliberate surgically created abdominal fistula is acceptable
Patient must have no history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within  weeks prior to randomization
No history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within past  months
Patients are excluded if they have history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within  months prior to randomization
History of abdominal fistula, GI perforation, or intra-abdominal abscess within  months prior to Day .
Subjects with a history of abdominal fistula, gastrointestinal perforation, intra-abdominal abscess; clinical signs or symptoms of GI obstruction and/or requirement for parenteral hydration or nutrition. In addition, subjects with other known clinically significant gastrointestinal disease including, but not limited to, inflammatory bowel disease.
Serious or non-healing wound, ulcer, or bone fracture or history of abdominal fistula, gastrointestinal perforation, intra-abdominal abscess major surgical procedure, open biopsy, or significant traumatic injury within  days prior to registration, with the exception of the craniotomy for tumor resection
Serious or non-healing wound, ulcer, or bone fracture or history of abdominal fistula, gastrointestinal perforation, intra-abdominal abscess major surgical procedure, open biopsy, or significant traumatic injury within  days prior to registration, with the exception of the craniotomy for tumor resection
Patients with a history of abdominal fistula, gastrointestinal perforation, or intraabdominal abscess within  months prior to Day 
History of intra-abdominal abscess within  months prior to starting treatment
History of abdominal/pelvic fistula, gastrointestinal perforation and/or intraabdominal abscess within  months prior to day 
Participants may not have had a history of intra-abdominal abscess within the past  months
Has a history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within  months prior to start of study drug
History of abdominal fistula, gastrointestinal perforation, peptic ulcer, or intra-abdominal abscess within  months
Patients with a history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the previous  months are not eligible for participation
No history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within  days prior to registration
History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within  months prior to day 
No history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within  months prior to enrollment
History of abdominal fistula, gastrointestinal perforation, or intraabdominal abscess =<  months prior to randomization
History of abdominal fistula, gastrointestinal perforation, bowel obstruction, gastric outlet obstruction, or intra-abdominal abscess within six months of study enrollment
Patients with a history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within  months prior to study enrollment
History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within  months prior to study enrollment
History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within  months prior to study registration
Patients with a history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within  months prior to planned day  of dosing are ineligible
History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within  months prior to study entry
History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within  months prior to Day 
Subjects with a History of bowel obstruction, including sub?occlusive disease, related to the underlying\r\ndisease and history of abdominal fistula, gastrointestinal perforation or intra?abdominal abscess
History of gastrointestinal perforation, abdominal fistula or intra-abdominal abscess within  months of enrollment.
History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess
Abdominal fistula, gastrointestinal (GI) perforation, or intra-abdominal abscess within  months
History of abdominal or tracheo-oesophageal fistula or gastrointestinal (GI) perforation or intra abdominal abscess within  months prior to Day  of Cycle 
Patients with an abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within  months
Conditions likely to increase the potential for abdominal perforation or fistula formation, including but not limited to: Luminal intestinal cancers or bulky abdominal disease. Presence or history of abdominal fistula, gastrointestinal perforation, peptic ulcer disease or intra-abdominal abscess within the six months prior to the first dose of GSK. Other risk factors for perforation, such as acute diverticulitis, obstruction or previous abdominal or pelvic radiation.
History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess =<  months prior to registration
Active peptic ulcer disease or history of abdominal fistula, GI perforation, or intra abdominal abscess within  days prior to enrolment
Evidence of abdominal fistula, gastrointestinal (GI) perforation or intraabdominal abscess
Patients with any of the following conditions are excluded: serious or non-healing wound, ulcer; history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within  days of treatment; coronary/peripheral artery bypass graft or stenting within the past  months; or cerebrovascular accident (CVA) or transient ischemic attack within the past  months
History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within  months prior to study enrollment
History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within  days of treatment
History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within  months prior to day 
History of an abdominal fistula, gastrointestinal (GI) perforation, or intra-abdominal abscess within previous  months
History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within  days prior to registration
History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within  months prior to study screening
No history of bowel obstruction, abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within past  months
Patients must not have known contraindications to bevacizumab, including but not limited to abdominal fistula, gastrointestinal (GI) perforation, intra-abdominal abscess, thrombotic or hemorrhagic disorders, uncontrolled hypertension or active clinically significant cardiovascular disease, non-healing wound, ulcer, or bone fracture within previous  weeks
Patient must not have a history of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess =<  months prior to study entry
